Birchview Capital’s 10x Genomics TXG Stock Holding History

Birchview Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59,000	Closed	-$962K	–	82
2025 Q4	$962K	Buy	+59,000	New	+$891K	0.56%	39
2025 Q3	–	Sell	-22,000	Closed	-$255K	–	77
2025 Q2	$255K	Sell	22,000 -28,000	-56%	-$255K	0.25%	55
2025 Q1	$437K	Hold	50,000	–	–	0.38%	36
2024 Q4	$718K	Buy	50,000 +20,000	+67%	+$316K	0.58%	25
2024 Q3	$677K	Hold	30,000	–	–	0.59%	26
2024 Q2	$584K	Hold	30,000	–	–	0.54%	27
2024 Q1	$1.13M	Hold	30,000	–	–	0.92%	24
2023 Q4	$1.68M	Buy	30,000 +9,000	+43%	+$392K	1.31%	18
2023 Q3	$866K	Buy	21,000 +9,000	+75%	+$468K	0.74%	24
2023 Q2	$670K	Buy	12,000 +2,000	+20%	+$108K	0.5%	31
2023 Q1	$558K	Hold	10,000	–	–	0.44%	32
2022 Q4	$364K	Buy	+10,000	New	+$327K	0.26%	39

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Birchview Capital's TXG Position: Q1 2026 in Review

Birchview Capital sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 59,000 shares — an estimated $962K sold.

Birchview Capital first reported a position in TXG in Q4 2022 and held it in 12 quarters. The position peaked at $1.68M in Q4 2023. 331 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Birchview Capital reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
Birchview Capital sold 59,000 10x Genomics shares in Q1 2026, an estimated $962K.
Birchview Capital first reported a position in 10x Genomics in Q4 2022 and held it in 12 quarters.
Birchview Capital's 10x Genomics position peaked at $1.68M in Q4 2023.
331 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.